Home : FDA Drug Database : Abraxane : Newsfeeds

Abraxane - Newsfeeds

Everolimus Stent Tops in Comparative Trial: Explain to interested patients that this report suggests that clinical outcomes for nondiabetic patients may be superior with the Xience everolimus-eluting stent than with the paclitaxel-eluting Taxus stent. An everolimus-eluting stent (Xience) produced ...
ELCC: Sorafenib (Nexavar) Fails to Boost NSCLC Survival: Patients treated with sorafenib plus carboplatin/paclitaxel chemotherapy had virtually identical survival to that of patients who received only chemotherapy, Giorgio Scagliotti, M.D., of the University of Torino in Italy, reported at the European Lung ...
Drug combo helps women with early breast cancer: SAN ANTONIO (AP) -- New drug combinations are helping women with early breast cancer. Using two drugs that more precisely target tumors doubled the number of women whose cancer disappeared compared to those who had only one of the drugs, doctors reported ...
Avastin for Breast Cancer Treatment: An EMA regulatory panel stated that Avastin should not be used with the chemotherapy docetaxel (Taxotere), but it can still be used with paclitaxel. “We are pleased that the EMA has confirmed the benefits of Avastin with paclitaxel and that Avastin ...
Geron Initiates Randomized Phase 2 Clinical Trial of Imetelstat in Breast Cancer: (BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN - News ) today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or without ...
Reportlinker Adds Breast Cancer Drug Futures: Espicom's Breast Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic ...
Questions and Answers about Avastin: Q1. Why is FDA proposing that the breast cancer indication for Avastin be removed? A1. FDA is proposing that the breast cancer indication for Avastin be removed based on results from required clinical studies of the drug, including the AVADO and RIBBON1 ...
Celgene 4th-qtr profit falls on acquisition charges: BOSTON, Jan 27 (Reuters) - Celgene Corp ( Symbol : CELG ) said on Thursday that its fourth-quarter net earnings fell 16 percent as acquisition-related charges offset higher sales of its cancer drugs. Sales of Revlimid, the company's treatment for multiple ...
2nd UPDATE: Celgene 4Q Profit Down 16% As Revenue Jumps: The deal is part of an effort to expand beyond its strength in blood cancer treatments by increasing its presence overseas and pushing into treating other cancers with Abraxane, which is a form of chemotherapy. Earlier this month, Celgene disclosed that ...
Q4 Sales Swell at Celgene: Thalomid sales were $91 million, down 17%. Net sales of Abraxane, added to the portfolio with the purchase of Abraxis BioScience, were $71 million in the reported quarter. Research and development (R&D) spend climbed 62.4% to $327.5 million in the reported quarter.

Patient Discussions:: Patient Discussions are not a substitute for professional medical advice, diagnosis, or treatment. Never delay or disregard seeking professional medical advice from your physician or other qualified health provider because of something you have read on ...
Hormone Therapy: Endometrial cancer is a cancerous growth of the endometrium (lining of the uterus). It is the most common uterine cancer. Aromatase inhibitors block aromatase, an enzyme that is a major source of estrogen in many major body tissues including the breast ...
Prevention and Lifestyle Factors: In spite of some rumors published in the popular press, antiperspirants or use of deodorants after shaving have not been linked with any higher risk for breast cancer. Tamoxifen and Other SERMs. Drugs known as selective estrogen-receptor modulators (SERMs ...
Celgene to buy Abraxis for $2.9B in biotech deal: The company is hoping it will be able to "re-energize" sales of Abraxis' only approved drug, the breast cancer treatment Abraxane, and also win approval for Abraxane as a treatment for skin, lung, and pancreatic cancer. If that happens, the value of the ...
Drugs Can Help Fight Breast Cancer: The most popular breast cancer treatment drugs today are Femara, Tamoxifen, Abraxane, Zometa and Herceptin. Femara is an aromatase inhibitor given in pill form. When used in conjunction with or after surgery, it can reduce the recurrence of breast cancer.
AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created ...: and a Phase 1b trial in combination with paclitaxel (Taxol®) in patients with metastatic breast cancer. A Phase 1b trial evaluating tivozanib as monotherapy in patients with non-small cell lung cancer is also being ...
Three-year SYNTAX results extend CABG advantage to intermediate-risk patients: ... mark: "intermediate-risk" patients with complex coronary disease by SYNTAX score are probably better off getting open-heart surgery than PCI with a Taxus paclitaxel-eluting stent, investigators say. Cumulative ...
MediGene AG (DE) - MediGene Obtains Additional US Patent Protection: EndoTAG(TM)-1 is a combination of positively charged liposomes with the therapeutic substance Paclitaxel embedded therein. EndoTAG(TM)-1 is MediGene's first product candidate derived from the EndoTAG(TM) platform ...
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel ...: including paclitaxel (Taxol(R)) resistant HCT-15 human colorectal cancer cells and the growth of tumor in in vivo model of nude mice injected with paclitaxel-resistant HCT-15 human colorectal cancer cells. "
Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular ...: ... clinical trials between two drug eluting stents – Abbott's XIENCE V® Everolimus Eluting Coronary Stent System and Boston Scientific's TAXUS® Express Paclitaxel-Eluting Coronary Stent System. In addition,

Looking for an Abraxane attorney in District of Columbia? Get in touch with one of our Abraxane attorneys in District of Columbia now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Pages: 1 2 3 4 Next

Need An Abraxane Attorney?

First Name Last Name Email Address State

Legal Issue

FDA Drug Database: Abraxane Click to select a Legal Issue

Has Your Health Been Negatively Affected?

Please Describe the Injury

close this window

Abraxane Information

Click to View Our Legal Resources

Looking for an Abraxane attorney in District of Columbia? Get in touch with one of our Abraxane attorneys in District of Columbia now.

LegalView.info is sponsored by law firms with offices in many states. This website contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Your access to this site does not constitute a legal attorney-client relationship. The choice of a lawyer is an important decision and should not be based solely upon advertisements. To access important information concerning the sponsors and their commitment to the ethical practice of law, click here.

The participating law firms are as follows: Anapol Schwartz (Philadelphia, Pennsylvania; Cherry Hill, New Jersey; Media, Pennsylvania; Reading, Pennsylvania; Wheeling, WV). Cohen, Placitella & Roth (Red Bank, New Jersey; Philadelphia, Pennsylvania). J. F. Humphreys (Charleston, West Virginia). Lopez McHugh (Newport Beach, California; Philadelphia, PA; and Moorestown, NJ). Click here for more information about these law firms.

Some of our partner firms do not accept some types of cases. For details on these case exceptions, click here.

20120517-104837

Close (x)

Looking for an Attorney?

Please type your question:

First Name:
Last Name:
E-mail:
Phone Number *
() -

State * Legal Issue *

FDA Drug Database: Abraxane Click to select a Legal Issue

Close (x)

Find Legal Help for Your Abraxane Case - Submit Your Information Below

Do you need legal assistance with your Abraxane case?
LegalView may be able to help.

Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *

Last name *

Email Address *

Phone Number *
() -

State *

Legal Issue * FDA Drug Database: Abraxane Change

Was There an Injury?

Please Describe The Injury

Please State Your Question *

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.

This form is secure and encrypted. More information about secure forms and your privacy here.